Monitoring and responding to signals of suicidal ideation in pragmatic clinical trials: Lessons from the GRACE trial for Chronic Sickle Cell Disease Pain
Contemporary Clinical Trials Communications · 2023-12 · 36 · 101218
DOI: 10.1016/j.conctc.2023.101218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contemporary Clinical Trials Communications, 2023-12. Verfasst von Eric S Swirsky und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Illinois Chicago, Chicago, IL, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCCIH NIH HHS, National Institutes of Health, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Sickle cell disease (SCD) is a hemoglobin disorder and the most common genetic disorder that affects 100,000 Americans and millions worldwide. Adults living with SCD have pain so severe that it often requires opioids to keep it in control. Depression is a major global public health concern associated with an increased risk in chronic medical disorders, including in adults living with sickle cell disease (SCD). A strong relationship exists between suicidal ideation, suicide attempts, and depression. Researchers enrolling adults living with SCD in pragmatic clinical trials are obligated to design their methods to deliberately monitor and respond to symptoms related to depression and suicidal ideation. This will offer increased protection for their participants and help clinical investigators meet their fiduciary duties. This article presents a review of this sociotechnical milieu that highlights, analyzes, and offers recommendations to address ethical considerations in the development of protocols, procedures, and monitoring activities related to suicidality in depressed patients in a pragmatic clinical trial.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Illinois Chicago, Chicago, IL, USA.
- University of Florida, Gainesville, FL, USA.
- Duke University, Durham, NC, USA.
- Duke Clinical Research Institute, Durham, NC, USA.
Förderung
- NCCIH NIH HHS
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke
- National Center for Complementary and Integrative Health
Zitieren
APA
Swirsky, E. S., Boyd, A. D., Gu, C., Burke, L. A., Doorenbos, A. Z., Ezenwa, M. O., Knisely, M. R., Leigh, J. W., Li, H., Mandernach, M. W., Molokie, R. E., Patil, C. L., Steffen, A. D., Shah, N., deMartelly, V. A., Staman, K. L., & Schlaeger, J. M. (2023). Monitoring and responding to signals of suicidal ideation in pragmatic clinical trials: Lessons from the GRACE trial for Chronic Sickle Cell Disease Pain. Contemporary Clinical Trials Communications, 36, 101218. https://doi.org/10.1016/j.conctc.2023.101218
Vancouver
Swirsky ES, Boyd AD, Gu C, Burke LA, Doorenbos AZ, Ezenwa MO, et al. Monitoring and responding to signals of suicidal ideation in pragmatic clinical trials: Lessons from the GRACE trial for Chronic Sickle Cell Disease Pain. Contemporary Clinical Trials Communications. 2023;36:101218. doi:10.1016/j.conctc.2023.101218
BibTeX
@article{Swirsky2023,
author = {Swirsky, Eric S and Boyd, Andrew D and Gu, Carol and Burke, Larisa A and Doorenbos, Ardith Z and Ezenwa, Miriam O and Knisely, Mitchell R and Leigh, Jonathan W and Li, Hongjin and Mandernach, Molly W and Molokie, Robert E and Patil, Crystal L and Steffen, Alana D and Shah, Nirmish and deMartelly, Victoria A and Staman, Karen L and Schlaeger, Judith M},
title = {Monitoring and responding to signals of suicidal ideation in pragmatic clinical trials: Lessons from the GRACE trial for Chronic Sickle Cell Disease Pain},
journal = {Contemporary Clinical Trials Communications},
year = {2023},
volume = {36},
pages = {101218},
doi = {10.1016/j.conctc.2023.101218}
}
EUVIMED